NORD Refines Orphan Exclusivity Position
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.